UBS reported on Thursday that it has raised estimates on drugstore chain, CVS Caremark Corporation (CVS).
The firm has increased its estimates for CVS, and had given the company a $60 price target. This price target suggests a 12% upside from the stock’s current price of $52.90.
Analysts have raised estimates on the company based on the potential benefits to the company from the health reform in 2014-2015.
CVS shares were mostly flat during premarket trading Thursday. The stock has increased 16% in the past year.
The Bottom Line
Shares of CVS Caremark Corporation (CVS) have a 1.70% yield, based on Wednesday’s closing price of $52.90.
CVS Caremark Corporation (CVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.